Simvastatin-induced cardiac autonomic control improvement in fructose-fed female rats

Clinics

Volumn 66, Issue 10, 2011, Pages 1793-1796

  da Silva, Renata Juliana ^b,c   Bernardes, Nathalia ^a,b   Brito, Janaina de O ^a   Sanches, Iris Callado ^a,c   Irigoyen, Maria Cláudia ^c   de Angelis, Kátia ^a  

^a UNIVERSIDADE NOVE DE JULHO   (Brazil)

^b SÃO JUDAS TADEU UNIVERSITY   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Arterial pressure; Autonomic function; Female; Fructose; Statin

Indexed keywords

FRUCTOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ANIMAL; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DIET RESTRICTION; DISEASE MODEL; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; METABOLIC SYNDROME X; METABOLISM; PHYSIOLOGY; RAT; TIME; WISTAR RAT;

ANIMALS; AUTONOMIC NERVOUS SYSTEM; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DISEASE MODELS, ANIMAL; FASTING; FEMALE; FRUCTOSE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; METABOLIC SYNDROME X; RATS; RATS, WISTAR; SIMVASTATIN; TIME FACTORS;

EID: 80054721554     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011001000019     Document Type: Article

References (31)

1. Basciano H, Federico L, Adeli K. Fructose, insulin resistance and metabolic dyslipidemia. Nutr Metab. 2005;5:1-14.
2. Wiernsperger N, Geloen A, Rapin JR. Fructose and cardiometabolic disorders: the controversy will, and must, continue. Clinics. 2010;65:729-38, doi: 10.1590/S1807-59322010000700013.
3. Cunha TS, Farah V, Paulini J, Pazzine M, Elased KM, Marcondes FK, et al. Relationship between renal and cardiovascular changes in a murine model of glucose intolerance. Regul Pept. 2007;139:1-4, doi: 10.1016/j.regpep.2006. 11.023.
4. Hwang IS, Ho H, Hoffman BB, Reaven GM. Fructose induced insulin resistance and hypertension in rats. Hypertension. 1987;5:512-6.
5. Farah V, Elased KM, Chen Y, Key MP, Cunha TS, Irigoyen MC, et al. Nocturnal hypertension in mice consuming a high fructose diet. Auton Neurosci. 2006;130:41-50, doi: 10.1016/j.autneu.2006.05.006.
6. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999;34:1281-6.
7. Oliveira VLL, Moreira ED, Ida F, Santos MSB, Barreto Filho JAS, Irigoyen MC, et al. Statin treatment increases afferent pathway sensitivity of baroreflex. Circulation. 2004;110:200.
8. Gao L, Wang W, Li Y, Schultz HD, Liu D, Cornish KC, et al. Simvastatin Therapy Normalizes Sympathetic Neural Control in Experimental Heart Failure Roles of Angiotensin II Type 1 Receptors and NAD(P)H Oxidase. Circulation. 2005;112:1763-70, doi: 10.1161/CIRCULATIONAHA.105. 552174.
9. Li Z, Iwai M, Wu L, Chen LR, Jimo T, Suzuki J, Tsuda M, et al. Fluvastatin enhaces the inhibitory effects of a selective AT1 receptor Blocker, Valsartan on Atherosclerosis. Hypertension. 2004;44:758-63, doi: 10.1161/01.HYP.0000145179.44166.0f.
10. Mosca L, Ferris A, Fabunmi R, Robertson RM. Tracking women's awareness of heart disease: An American Heart Association National Study. Circulation. 2005;109:73-579.
11. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bombelli M, Mancia G. Metabolic syndrome and cardiometabolic risk: an update. Blood Press. 2009;18:7-16, doi: 10.1080/08037050802677695.
12. Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dL treated with statins versus no lipid-lowering drug. Am J Cardiol. 2002;89:67-9, doi: 10.1016/S0002-9149(01)02167-1.
13. Pehlivanidis AN, Athyros VG, Demitriadis DS, Papageorgiou AA, Bouloukos VJ, Kontopoulos AG. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis. 2001;157(2):43-9.
14. Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51:415-26.
15. Prinz V, Endres M. Statins and stroke: prevention and beyond. Curr Opin Neurol. 2011;24:75-80, doi: 10.1097/WCO.0b013e3283424c53.
16. Brito JO, Ponciano K, Figueroa D, Bernardes N, Sanches IC, Irigoyen MC, et al. Parasympathetic dysfunction is associated with insulin resistance in fructose-fed female rats. Braz J Med Biol Res. 2008;41:804-8, doi: 10.1590/ S0100-879X2008005000030.
17. Bonora E, Moghetti P, Zancanaro C, Cigolini M, Querena M, Cacciatoni V, et al. Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab. 1989;68:374-8, doi: 10.1210/jcem-68-2-374.
18. Farah Vde M, De Angelis K, Joaquim LF, Candido GO, Bernardes N, Fazan R Jr, et al. Autonomic modulation of arterial pressure and heart rate variability in hypertensive diabetic rats. Clinics. 2007;62:477-82, doi: 10.1590/S1807-59322007000400015.
19. Galipeau D, Verma S, Mcneill JH. Female rats are protected against fructose-induced changes in metabolism and blood pressure. Am J Physiol. 2002;283:2478-84.
20. Takagawa Y, Berger ME; Tuck MT, Golub MS. Impaired Endothelial Alpha-2 Adrenergic Receptor-Mediated Vascular Relaxation in the Fructose-Fed Rat. Hypertens Res. 2002;25:197-202, doi: 10.1291/hypres. 25.197.
21. Song D, Arikawa E, Galipeau D, Battell M, McNeil JH. Androgens Are Necessary for the Development of Fructose-Induced Hypertension. Hypertension. 2004;43:667-72, doi: 10.1161/01.HYP.0000118018.77344.4e.
22. Zhou SH, Ling HI, Tian SW, Liu XQ, Wang BX, Bi H. 17b-estradiol protects against injury of aortic relaxation and contraction in ovariectomized rats with insulin resistance induced by fructose. Acta Physiologica Sinica. 2005;57:627-35.
23. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Joint National Commitee on Prevention, Detection, Evaluatin and Treatment of High Blood Pressure. National High blood pressure Education Program Coordinating Commitee. Seventh Report of Joint National Commitee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42:1206-52, doi: 10.1161/01. HYP.0000107251.49515.c2.
24. Verma S, Bhanot S, Mcneill JH. Sympathectomy prevents fructoseinduced hyperinsulinemia and hypertension. Eur J Pharmacol. 1999;373:R1-4, doi: 10.1016/S0014-2999(99)00301-5.
25. Verma S, Bhanot S, Yao L, McNeill JH. Defective endothelium dependent relaxation in fructose-hypertensive rats. Am J Hypertens. 1996;9:370-6, doi: 10.1016/0895-7061(95)00392-4.
26. Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Failure Simvastatin Normalizes Autonomic Neural Control in Experimental Heart. Circulation. 2003;107:2493-8, doi: 10.1161/01.CIR.0000065606.63163.B9.
27. Mital S, Zhang XP, Zhao G, Bernstein RD, Smith CJ, Fulton DL, et al. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol. 2000;279:H2649-57.
28. Dobrucki LW, Kalinowski L, Dobrucki IT, Malinski T. Statin-stimulated nitric oxide release from endothelium. Med Sci Monit. 2001;7:622-7.
29. Park JK, Muller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure-and cholesterol-lowering effects. Kidney Int. 2000;58:1420-30, doi: 10.1046/j.1523-1755.2000.00304.x.
30. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhövel F, Böhm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 1999;100:2131-4.
31. Hernandez OP, Perez DS, Navarro JA, Sánchez-Pascuala R, Hernández G, Díazet C, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711-9, doi: 10.1172/JCI1500.